133 related articles for article (PubMed ID: 29549809)
61. The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.
Santini V; Almeida A; Giagounidis A; Platzbecker U; Buckstein R; Beach CL; Guo S; Altincatal A; Wu C; Fenaux P
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):136-144.e7. PubMed ID: 29429612
[TBL] [Abstract][Full Text] [Related]
62. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
[TBL] [Abstract][Full Text] [Related]
63. A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.
Pappa V; Anagnostopoulos A; Bouronikou E; Briasoulis E; Kotsianidis I; Pagoni M; Zikos P; Tsionos K; Viniou N; Meletis J; Papadaki H; Kioumi A; Galanopoulos A; Vervessou EC; Poulakidas E; Karmas P; Karvounis K; Symeonidis A
Int J Hematol; 2017 Feb; 105(2):184-195. PubMed ID: 27815858
[TBL] [Abstract][Full Text] [Related]
64. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Palumbo A; Freeman J; Weiss L; Fenaux P
Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
[TBL] [Abstract][Full Text] [Related]
65. Treatment of MDS: something old, something new, something borrowed..
Sekeres MA
Hematology Am Soc Hematol Educ Program; 2009; ():656-63. PubMed ID: 20008251
[TBL] [Abstract][Full Text] [Related]
66. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
67. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
[TBL] [Abstract][Full Text] [Related]
68. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
List AF; Baer MR; Steensma DP; Raza A; Esposito J; Martinez-Lopez N; Paley C; Feigert J; Besa E
J Clin Oncol; 2012 Jun; 30(17):2134-9. PubMed ID: 22547607
[TBL] [Abstract][Full Text] [Related]
69. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.
Sekeres MA; Schoonen WM; Kantarjian H; List A; Fryzek J; Paquette R; Maciejewski JP
J Natl Cancer Inst; 2008 Nov; 100(21):1542-51. PubMed ID: 18957672
[TBL] [Abstract][Full Text] [Related]
70. Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes.
Ghaderi A; Nodehi SRS; Bakhtiari T; Aslani M; Aghazadeh Z; Matsuo H; Rehm BHA; Cuzzocrea S; Mirshafiey A
J Clin Pharmacol; 2020 Jul; 60(7):879-888. PubMed ID: 32064621
[TBL] [Abstract][Full Text] [Related]
71. Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
Chen N; Kassir N; Laadem A; Maxwell SE; Sriraman P; Giuseppi AC; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):395-404. PubMed ID: 32602651
[TBL] [Abstract][Full Text] [Related]
72. Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms.
Zaidi SDEZ; Fatima Zaidi SM; Rangwala BS
Ann Hematol; 2024 Jun; 103(6):2163-2164. PubMed ID: 38652243
[No Abstract] [Full Text] [Related]
73. Imetelstat: Finally a disease-modifying treatment for lower-risk myelodysplastic syndromes?
Majidi F; Gattermann N
Med; 2024 Mar; 5(3):184-186. PubMed ID: 38460498
[TBL] [Abstract][Full Text] [Related]
74. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Garcia-Manero G; Mufti GJ; Fenaux P; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Ilhan O; Sekeres MA; Zeidan AM; Ito R; Zhang J; Rampersad A; Sinsimer D; Backstrom JT; Platzbecker U; Komrokji RS
Blood; 2022 Jan; 139(4):624-629. PubMed ID: 34758066
[No Abstract] [Full Text] [Related]
75. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
76. MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia.
Krejcik Z; Belickova M; Hrustincova A; Votavova H; Jonasova A; Cermak J; Dyr JE; Merkerova MD
Cancer Biomark; 2018; 22(1):101-110. PubMed ID: 29630523
[TBL] [Abstract][Full Text] [Related]
77. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
[TBL] [Abstract][Full Text] [Related]
78. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Díez-Campelo M; Lorenzo JI; Itzykson R; Rojas SM; Berthon C; Luño E; Beyne-Rauzy O; Perez-Oteyza J; Vey N; Bargay J; Park S; Cedena T; Bordessoule D; Muñoz JA; Gyan E; Such E; Visanica S; López-Cadenas F; de Botton S; Hernández-Rivas JM; Ame S; Stamatoullas A; Delaunay J; Salanoubat C; Isnard F; Guieze R; Pérez Guallar J; Badiella L; Sanz G; Cañizo C; Fenaux P
Br J Haematol; 2018 May; 181(3):350-359. PubMed ID: 29611196
[TBL] [Abstract][Full Text] [Related]
79. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.
Stauder R; Yu G; Koinig KA; Bagguley T; Fenaux P; Symeonidis A; Sanz G; Cermak J; Mittelman M; Hellström-Lindberg E; Langemeijer S; Holm MS; Mądry K; Malcovati L; Tatic A; Germing U; Savic A; van Marrewijk C; Guerci-Bresler A; Luño E; Droste J; Efficace F; Smith A; Bowen D; de Witte T
Leukemia; 2018 Jun; 32(6):1380-1392. PubMed ID: 29572506
[TBL] [Abstract][Full Text] [Related]
80. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
